<DOC>
	<DOCNO>NCT00420238</DOCNO>
	<brief_summary>Evaluation efficacy safety etanercept ( Enbrel ) patient active , severe advance ankylose spondylitis .</brief_summary>
	<brief_title>Study Evaluating Etanercept Treatment Active , Severe , Advanced Axial Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criterion Active severe ankylose spondylitis Ankylosing spondylitis refractory standard antirheumatic treatment Between 18 70 year age Exclusion criterion Prior exposure TNFinhibitor , include etanercept DMARDs ( hydroxychloroquine , methotrexate sulphasalazine ) within 4 week study drug initiation Dose NSAIDs change within two week study drug initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Axial Ankylosing Spondylitis</keyword>
	<keyword>Adult</keyword>
</DOC>